LLY

762.79

+0.4%↑

JNJ

174.31

-1.4%↓

ABBV

221.87

+0.84%↑

UNH

334.97

-1.8%↓

AZN

77.08

-0.7%↓

LLY

762.79

+0.4%↑

JNJ

174.31

-1.4%↓

ABBV

221.87

+0.84%↑

UNH

334.97

-1.8%↓

AZN

77.08

-0.7%↓

LLY

762.79

+0.4%↑

JNJ

174.31

-1.4%↓

ABBV

221.87

+0.84%↑

UNH

334.97

-1.8%↓

AZN

77.08

-0.7%↓

LLY

762.79

+0.4%↑

JNJ

174.31

-1.4%↓

ABBV

221.87

+0.84%↑

UNH

334.97

-1.8%↓

AZN

77.08

-0.7%↓

LLY

762.79

+0.4%↑

JNJ

174.31

-1.4%↓

ABBV

221.87

+0.84%↑

UNH

334.97

-1.8%↓

AZN

77.08

-0.7%↓

Search

Bio-Techne Corp

Fermé

SecteurSoins de santé

53.01 3.07

Résumé

Variation du prix de l'action

24h

Actuel

Min

51.53

Max

53.25

Chiffres clés

By Trading Economics

Revenu

-40M

-18M

Ventes

783K

317M

P/E

Moyenne du Secteur

112.217

35.293

BPA

0.53

Rendement du dividende

0.62

Marge bénéficiaire

-5.577

Employés

3,100

EBITDA

-61M

6.4M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+27.46% upside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

0.62%

3.07%

Prochains Résultats

29 oct. 2025

Date du Prochain Dividende

21 nov. 2025

Date du Prochain Détachement de Dividende

10 nov. 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-861M

8B

Ouverture précédente

49.94

Clôture précédente

53.01

Sentiment de l'Actualité

By Acuity

27%

73%

70 / 371 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Weak Bullish Evidence

Bio-Techne Corp Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

17 sept. 2025, 23:01 UTC

Acquisitions, Fusions, Rachats

Santos Confirms XRG Consortium Pulls $18.7 Billion Takeover Bid -- Update

17 sept. 2025, 22:48 UTC

Acquisitions, Fusions, Rachats

Santos Confirms XRG Consortium Pulls $18.7 Billion Takeover Bid

17 sept. 2025, 21:59 UTC

Résultats

Cryptocurrency-Exchange Bullish Swings to Profit in First Report as Public Company

17 sept. 2025, 23:44 UTC

Market Talk

Nikkei May Rise as Yen Weakens -- Market Talk

17 sept. 2025, 23:39 UTC

Market Talk

Gold Rises Amid Prospects of Further Fed Rate Cuts -- Market Talk

17 sept. 2025, 22:20 UTC

Acquisitions, Fusions, Rachats

Santos: XRG Consortium Wouldn't Agree to Appropriate Risk Allocation Between It and Santos Shareholders

17 sept. 2025, 22:20 UTC

Acquisitions, Fusions, Rachats

Santos: XRG Consortium Wouldn't Agree to Acceptable Terms That Protected Value of Transaction

17 sept. 2025, 22:20 UTC

Acquisitions, Fusions, Rachats

Santos Had Expressed Concern to XRG Consortium About Delays in Agreeing to Scheme Implementation Agreement

17 sept. 2025, 22:19 UTC

Acquisitions, Fusions, Rachats

Santos: Consortium Notified Board of Decision to Withdraw Proposal on Weds Evening

17 sept. 2025, 22:18 UTC

Acquisitions, Fusions, Rachats

Santos Confirms XRG Consortium Has Withdrawn Takeover Proposal

17 sept. 2025, 21:00 UTC

Résultats

Darden Restaurants to Report Earnings. Why the Olive Garden Parent Is Expected to Stay Strong. -- Barrons.com

17 sept. 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

17 sept. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

17 sept. 2025, 19:59 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17 sept. 2025, 19:59 UTC

Market Talk

Treasury Yields, Dollar Rise as Fed Cuts, Powell Warns of Risks -- Market Talk

17 sept. 2025, 19:07 UTC

Market Talk

Oil Futures Snap Three-Session Winning Streak -- Market Talk

17 sept. 2025, 18:43 UTC

Market Talk

Treasury Yields, Dollar Reverse Course as Powell Talks to Reporters -- Market Talk

17 sept. 2025, 18:38 UTC

Market Talk

U.S. Natural Gas Futures Mixed Ahead of Storage Data -- Market Talk

17 sept. 2025, 18:20 UTC

Market Talk

Gold Dips After Quarter-Point Rate Cut -- Market Talk

17 sept. 2025, 18:18 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17 sept. 2025, 18:18 UTC

Market Talk

Treasury Yields, Dollar Fall on Nearly Unanimous Fed Cut -- Market Talk

17 sept. 2025, 18:14 UTC

Market Talk

Oil Slips Some More as Fed Makes Expected 25 Bp Rate Cut -- Market Talk

17 sept. 2025, 17:59 UTC

Market Talk

Soyoil Takes Hit as Traders Consider EPA Proposal -- Market Talk

17 sept. 2025, 17:15 UTC

Acquisitions, Fusions, Rachats

Netflix 'Has Won The Streaming Wars,' Analyst Says. The Stock Is a Buy. -- Barrons.com

17 sept. 2025, 17:06 UTC

Acquisitions, Fusions, Rachats

Walmart Stock Heads for a Record High. The Retailer Could Become a Leader in 'Agentic' AI. -- Barrons.com

17 sept. 2025, 16:51 UTC

Résultats

Correct: Exor 1H Net Loss -EUR624M

17 sept. 2025, 16:34 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17 sept. 2025, 16:34 UTC

Market Talk

Bank of Canada Ditches Resilience Talk, Plays Up Slowing Growth -- Market Talk

17 sept. 2025, 16:25 UTC

Résultats

Wolters Kluwer: July, August Saw a Slight Increase in Organic Growth Compared to 1H

17 sept. 2025, 16:23 UTC

Résultats

Wolters Kluwer: Year-to-Date Performance In Line With 2025 Guidance

Comparaison

Variation de prix

Bio-Techne Corp prévision

Objectif de Prix

By TipRanks

27.46% hausse

Prévisions sur 12 Mois

Moyen 66 USD  27.46%

Haut 75 USD

Bas 53 USD

Basé sur 13 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

13 ratings

10

Achat

3

Maintien

0

Vente

Score Technique

By Trading Central

49.67 / 50.24Support & Résistance

Court Terme

Weak Bullish Evidence

Moyen Terme

Weak Bullish Evidence

Long Terme

Strong Bearish Evidence

Sentiment

By Acuity

70 / 371Classement par Soins de santé

Sentiment de l'Actualité

Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Supérieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Bio-Techne Corp

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company has strategic partnership with ALZpath, Inc. to accelerate breakthroughs in neurodegenerative disease research and treatment, including Alzheimer's disease. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
help-icon Live chat